Antiretroviral drugs in HIV-infected children

Pharmacological Research

Volumn 64, Issue 1, 2011, Pages 1-3

  Viganò, Alessandra ^a   Manfredini, Valeria ^a   Penagini, Francesca ^a   Giacomet, Vania ^a   Zuccotti, Gian Vincenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiretroviral drugs; Children; HIV

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; TENOFOVIR; ZIDOVUDINE;

BODY FAT DISTRIBUTION; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; INJECTION SITE REACTION; INSULIN RESISTANCE; LIVER TOXICITY; LOW DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; INFANT;

EID: 79955682136     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.01.007     Document Type: Review

References (15)

1. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access; 2010. http://www.who.int/hiv/ pub/paediatric/infants2010/en/index.html. Accessed October 22, 2010.
2. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretrovirals agents in paediatric HIV infection; August 16, 2010. Available at http://aidsinfo.nih.gov/contentfiles/ PediatricGuidelines.pdf. Accessed September 15, 2010.
3. PENTA Steering Committee, Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009;10:591-613.
4. HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006;20:1289-94.
5. HIV Paediatric Prognostic Markers Collaborative Study. Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS 2010;24:1213-7.
6. Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, et al. HIV-NAT 086 Study Team. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med 2010;11:565-72. Epub 2010 March 25.
7. Aulicino PC, Rocco CA, Mecikovsky D, Bologna R, Mangano A, Sen L. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74Vmutations. Antiviral Ther 2010;15:641-50.
8. Fernández-Montero JV, Barreiro P, Soriano V. HIV protease inhibitors: recent clinical trials and recommendations on use. Expert Opin Pharmacother 2009;10(July):1615-29.
9. McKeage K, Scott LJ. Darunavir: in treatment-experienced pediatric patients with HIV-1 infection. Paediatr Drugs 2010;12(April):123-31.
10. Eron Jr J, Yeni P, Gathe Jr J, Estrada V, DeJesus E, Staszewski S, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368:476-82. (Pubitemid 44160731)
11. Palladino C, Briz V, Policarpo SN, Silveira LF, de José MI, González-ToméMI, et al. Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J 2010;29:563-6.
12. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ HIVandAIDSActivities/ucm118951.htm. Accessed October 22, 2010.
13. Schafer JJ, Short WR, Squires KE. Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus. Pharmacotherapy 2010;30:1072-83.
14. Palladino C, Briz V, González-Tomé MI, Leon Leal JA, Navarro ML, de Josè MI, et al. Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials. AIDS Res Hum Retroviruses 2010;26:301-5.
15. Interim IMPAACT Results Show Raltegravir (Isentress) Is Safe and Effective for Children and Adolescents with HIV. In: 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009). 2009.